Unique Diacidic Fragments Inhibit the OXA-48 Carbapenemase and Enhance the Killing of Escherichia coli Producing OXA-48.
Sign Up to like & getrecommendations! Published in 2021 at "ACS infectious diseases"
DOI: 10.1021/acsinfecdis.1c00501
Abstract: Despite the advances in β-lactamase inhibitor development, limited options exist for the class D carbapenemase known as OXA-48. OXA-48 is one of the most prevalent carbapenemases in carbapenem-resistant Enterobacteriaceae infections and is not susceptible to… read more here.
Keywords: inhibit oxa; inhibitor development; escherichia coli; carbapenemase ... See more keywords
Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan.
Sign Up to like & getrecommendations! Published in 2020 at "Thrombosis and haemostasis"
DOI: 10.1055/s-0040-1721385
Abstract: Some genetic and treatment-related factors are risk factors for inhibitor development in patients with hemophilia A (PwHA). However, the genotype distribution of the factor VIII gene (F8) and genetic impact on inhibitor development in Japanese… read more here.
Keywords: inhibitor development; genetic impact; inhibitor; impact inhibitor ... See more keywords
Interleukin 10, but not tumor necrosis factor-alpha, gene variations are associated with factor VII inhibitor development.
Sign Up to like & getrecommendations! Published in 2023 at "Laboratory medicine"
DOI: 10.1093/labmed/lmad026
Abstract: OBJECTIVE Development of alloantibodies against coagulation factor VII (FVII) is the main therapeutic challenge in severe congenital FVII deficiency. About 7% of patients with severe congenital FVII deficiency develop an inhibitor against FVII. In this… read more here.
Keywords: factor vii; development; factor; inhibitor development ... See more keywords
Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14503
Abstract: Inhibitor development affects about 30% of patients with severe haemophilia A (HA) and results from different environmental and genetic risk factors. Previously, we identified the missense variant rs3754689 in the LCT gene linked with this… read more here.
Keywords: inhibitor development; severe haemophilia; patients severe; region ... See more keywords
Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14553
Abstract: Factor (F) VIII inhibitors develop in around 30% of previously untreated patients (PUPs) with severe haemophilia, to a lesser extend in moderate and mild haemophilia A and in up to 10% in severe haemophilia B.… read more here.
Keywords: inhibitor; factor; diagnostic challenges; inhibitor development ... See more keywords
Clinical conditions and risk factors for inhibitor‐development in patients with haemophilia: A decade‐long prospective cohort study in Japan, J‐HIS2 (Japan Hemophilia Inhibitor Study 2)
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14602
Abstract: Inhibitor‐development is a serious complication in patients with haemophilia (PwH). Previous studies reported that therapeutic and genetic factors could be associated with these alloantibodies. Relevant clinical features such as genetic‐background and different treatment regimens in… read more here.
Keywords: inhibitor development; patients haemophilia; japan; study ... See more keywords
Methylome analysis for haemophilia A intron 22 inversion patients with and without inhibitors: A pilot study
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14651
Abstract: Pathogenic variants in the FVIII gene ( F8 ) cause haemophilia A. The most frequent variant is the intron 22 gene inversion, which causes nearly 45% of severe cases. 1 Factor VIII (FVIII) replacement ther-apy… read more here.
Keywords: inhibitor development; intron; inversion; inhibitor ... See more keywords
Ameliorating effects of bortezomib, a proteasome inhibitor, on development of dextran sulfate sodium-induced murine colitis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Biochemistry and Nutrition"
DOI: 10.3164/jcbn.18-42
Abstract: We examined the effect of bortezomib, a proteasome inhibitor, on the development of dextran sulfate sodium (DSS)-induced colitis in mice. DSS-colitis was induced by the administration of 3% DSS in water in C57BL/6J mice. Bortezomib… read more here.
Keywords: proteasome inhibitor; bortezomib proteasome; inhibitor development; colitis ... See more keywords